Overview

Effects of Cholecalciferol on Osteoprotegerin Levels in Patients on Peritoneal Dialysis

Status:
Unknown status
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
Aim: To investigate whether cholecalciferol (4800 U/daily) or placebo for 16 weeks reduces proteins levels associated with vascular calcification (osteoprotegerin, osteopontin, osteocalcin) in patients treated with peritoneal dialysis and 25(OH) vitamin D deficiency.
Phase:
Phase 4
Details
Lead Sponsor:
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Treatments:
Cholecalciferol